Thank you. I appreciate that.
Mr. Easter finds himself in a tough spot. The tough spot he finds himself in is that he supported Mr. Atamanenko's bill at all of its stages. Mr. Atamanenko's bill ran out of time. Forget the fact that I can't remember the number of months it sat in front of Parliament. It still wasn't enough time for Mr. Atamanenko. It's because he saw the end coming that he passed a motion for an extension.
Mr. Chair, a motion came forward before that. Witnesses came in front of this committee to say that the prolonged debate or simply the lengthy debate on Mr. Atamanenko's motion or bill was actually having a detrimental impact on the research and development sector of agriculture. They talked about investors, companies that would normally invest in biotechnology and in research and development in Canada. We have a fairly robust research and development sector. They came in front of the committee to say that with Mr. Atamanenko's bill in front of the House, it was sowing uncertainty in the field. It was actually giving investors pause. They were withholding decisions in favour of our research and development sector.
They were coming to see me. If they were coming to see me and my colleagues on the committee, I'm certain they were going to see Mr. Easter and Mr. Valeriote. In fact, we had many discussions on who was coming to see us, despite the breakdown in relations at committee. We had better relations at that time and we were communicating as we should, being members of the agriculture committee. I know they went to see Mr. Easter and Mr. Valeriote to explain the concern they had that Mr. Atamanenko's bill on GM was hurting the sector.
What did Mr. Easter do? Despite all of that, he voted in favour of this committee reporting back to the House to ask for an extension to Mr. Atamanenko's bill. When it got to the House, we had debate on whether it should be extended or should not be extended. Mr. Easter again voted for the extension, not only in committee but in the House, and that Parliament should give more time to Mr. Atamanenko's bill. It's all on the public record. Mr. Valeriote voted that way as well.
Mr. Easter was basically sending a message to people who would support the position that he's with Mr. Atamanenko a hundred percent. He was a hundred percent on board with the contents of Mr. Atamanenko's bill, every step of the way, vote after vote and debate after debate. Everything that Mr. Easter did in terms of action would lead the people who supported Mr. Atamanenko's bill to believe that Mr. Easter fully supported the bill. Then came the final vote in the House on Mr. Atamanenko's bill, and Mr. Easter voted against Mr. Atamanenko's bill.
Did he vote the right way in the end? Yes, he voted the right way in the end. I think the companies that were involved in research and development in the biotechnology sector in Canada were appreciative that Mr. Easter had finally, at the very end, voted against Mr. Atamanenko's bill.
Chair, you can imagine the surprise of the people, groups, and organizations that followed Mr. Easter's every move from the beginning of Mr. Atamanenko's bill. He voted for it, supported it, debated for it, and argued in favour of it. At the very last minute, at the last vote when the bill could actually pass into law, Mr. Easter then voted against it. He changed his colours. It was a 180-degree turn. You can imagine the shock.
What did they do? They got on to Mr. Easter. They started lobbying him, phoning him, peppering him with e-mails, and bringing tremendous pressure to bear. They may very well have mentioned that he was the president of the NFU for many years and that, as an organization, the NFU supported Mr. Atamanenko's bill.